King C - Search Results

1

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.

Nathan SD, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, De La Zerda DJ, Sahay S, King C, Melendres-Groves L, Smith P, Shen E, Edwards LD, Nelsen A, Tapson VF. Nathan SD, et al. Among authors: king c. Lancet Respir Med. 2021 Nov;9(11):1266-1274. doi: 10.1016/S2213-2600(21)00165-X. Epub 2021 Jun 29. Lancet Respir Med. 2021. PMID: 34214475 Clinical Trial.

2

Native lung complications in single-lung transplant recipients and the role of pneumonectomy.

King CS, Khandhar S, Burton N, Shlobin OA, Ahmad S, Lefrak E, Barnett SD, Nathan SD. King CS, et al. J Heart Lung Transplant. 2009 Aug;28(8):851-6. doi: 10.1016/j.healun.2009.04.023. J Heart Lung Transplant. 2009. PMID: 19632585

3

Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases.

King C, Nathan SD. King C, et al. Curr Opin Pulm Med. 2013 Sep;19(5):466-73. doi: 10.1097/MCP.0b013e328363f460. Curr Opin Pulm Med. 2013. PMID: 23912191 Review.

4

Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?

Nathan SD, King CS. Nathan SD, et al. Drug Des Devel Ther. 2014 Jul 2;8:875-85. doi: 10.2147/DDDT.S64907. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25061279 Free PMC article. Review.

5

Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease.

Shin S, King CS, Brown AW, Albano MC, Atkins M, Sheridan MJ, Ahmad S, Newton KM, Weir N, Shlobin OA, Nathan SD. Shin S, et al. Among authors: king cs. Respir Med. 2014 Nov;108(11):1626-32. doi: 10.1016/j.rmed.2014.08.009. Epub 2014 Sep 2. Respir Med. 2014. PMID: 25225149 Free article.

6

Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis.

King CS, Nathan SD. King CS, et al. Curr Opin Pulm Med. 2015 Sep;21(5):479-89. doi: 10.1097/MCP.0000000000000190. Curr Opin Pulm Med. 2015. PMID: 26164298 Review.

7

Organ Donors: Making the Most of What Is Offered.

Nathan SD, King CS. Nathan SD, et al. Chest. 2015 Aug;148(2):303-305. doi: 10.1378/chest.15-1269. Chest. 2015. PMID: 26238828 No abstract available.

8

Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis.

Shin S, King CS, Puri N, Shlobin OA, Brown AW, Ahmad S, Weir NA, Nathan SD. Shin S, et al. Eur Respir J. 2016 May;47(5):1445-51. doi: 10.1183/13993003.01532-2015. Epub 2016 Feb 4. Eur Respir J. 2016. PMID: 26846836 Free article.

9

POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.

King CS, Nathan SD. King CS, et al. Chest. 2016 Aug;150(2):273-5. doi: 10.1016/j.chest.2016.04.034. Epub 2016 Jun 9. Chest. 2016. PMID: 27292047 No abstract available.

10

Rebuttal From Drs King and Nathan.

King CS, Nathan SD. King CS, et al. Chest. 2016 Aug;150(2):278. doi: 10.1016/j.chest.2016.04.035. Epub 2016 Jun 9. Chest. 2016. PMID: 27292048 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,261 results

Search Page

Filters